CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2

David Asmuth, James Goodrich, David A. Cooper, Richard Haubrich, Natasa Rajicic, Bernard Hirschel, Howard Mayer, Hernan Valdez

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Objectives: To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients. Methods: Forty-eight-week data from MOTIVATE 1 and 2 was used to assess MVC once or twice daily versus placebo (PBO), each with optimized background therapy (N = 1047). A repeated measures model evaluated longitudinal CD4 changes, multivariate linear regression evaluated predictors of week 48 increases, and Cox proportional hazard modeling evaluated time to category C events. Results: Median CD4 increases were greater on MVC once or twice daily than PBO (92, 103, and 24 cells/mm3, respectively; P < 0.05), and the difference remained significant among patients achieving less than 50 HIV-1 RNA copies/mL (126, 125, and 96 cells/mm3; P < 0.05) or when adjusted for other predictors of CD4 increase including change in HIV-1 RNA. Time to a category C event was longer on MVC; in multivariate models, higher on-treatment CD4 count, but not MVC treatment, was protective against new events (hazard ratio 0.8 per +25 cells/mm3; 95% confidence interval 0.78-0.87). Conclusions: MOTIVATE patients receiving MVC had larger CD4+ T-cell increases than those receiving PBO, even after adjusting for the greater virologic potency of MVC-containing regimens. This additional CD4 response was associated with a longer time to the development of AIDS-defining events on MVC.

Original languageEnglish (US)
Pages (from-to)394-397
Number of pages4
JournalJournal of Acquired Immune Deficiency Syndromes
Volume54
Issue number4
DOIs
StatePublished - Aug 1 2010

Fingerprint

T-Lymphocytes
Placebos
Therapeutics
HIV-1
RNA
maraviroc
CD4 Lymphocyte Count
Linear Models
Acquired Immunodeficiency Syndrome
Confidence Intervals

Keywords

  • CCR5 antagonist
  • CD4 cell rises
  • clinical trials
  • immune restoration
  • maraviroc
  • opportunistic infections
  • treatment-experienced patients

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Medicine(all)

Cite this

CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. / Asmuth, David; Goodrich, James; Cooper, David A.; Haubrich, Richard; Rajicic, Natasa; Hirschel, Bernard; Mayer, Howard; Valdez, Hernan.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 54, No. 4, 01.08.2010, p. 394-397.

Research output: Contribution to journalArticle

Asmuth, David ; Goodrich, James ; Cooper, David A. ; Haubrich, Richard ; Rajicic, Natasa ; Hirschel, Bernard ; Mayer, Howard ; Valdez, Hernan. / CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. In: Journal of Acquired Immune Deficiency Syndromes. 2010 ; Vol. 54, No. 4. pp. 394-397.
@article{26f64e55a66048aa892a22e277f86eb8,
title = "CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2",
abstract = "Objectives: To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients. Methods: Forty-eight-week data from MOTIVATE 1 and 2 was used to assess MVC once or twice daily versus placebo (PBO), each with optimized background therapy (N = 1047). A repeated measures model evaluated longitudinal CD4 changes, multivariate linear regression evaluated predictors of week 48 increases, and Cox proportional hazard modeling evaluated time to category C events. Results: Median CD4 increases were greater on MVC once or twice daily than PBO (92, 103, and 24 cells/mm3, respectively; P < 0.05), and the difference remained significant among patients achieving less than 50 HIV-1 RNA copies/mL (126, 125, and 96 cells/mm3; P < 0.05) or when adjusted for other predictors of CD4 increase including change in HIV-1 RNA. Time to a category C event was longer on MVC; in multivariate models, higher on-treatment CD4 count, but not MVC treatment, was protective against new events (hazard ratio 0.8 per +25 cells/mm3; 95{\%} confidence interval 0.78-0.87). Conclusions: MOTIVATE patients receiving MVC had larger CD4+ T-cell increases than those receiving PBO, even after adjusting for the greater virologic potency of MVC-containing regimens. This additional CD4 response was associated with a longer time to the development of AIDS-defining events on MVC.",
keywords = "CCR5 antagonist, CD4 cell rises, clinical trials, immune restoration, maraviroc, opportunistic infections, treatment-experienced patients",
author = "David Asmuth and James Goodrich and Cooper, {David A.} and Richard Haubrich and Natasa Rajicic and Bernard Hirschel and Howard Mayer and Hernan Valdez",
year = "2010",
month = "8",
day = "1",
doi = "10.1097/QAI.0b013e3181c5c83b",
language = "English (US)",
volume = "54",
pages = "394--397",
journal = "Journal of acquired immune deficiency syndromes (1999)",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - CD4+ T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2

AU - Asmuth, David

AU - Goodrich, James

AU - Cooper, David A.

AU - Haubrich, Richard

AU - Rajicic, Natasa

AU - Hirschel, Bernard

AU - Mayer, Howard

AU - Valdez, Hernan

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Objectives: To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients. Methods: Forty-eight-week data from MOTIVATE 1 and 2 was used to assess MVC once or twice daily versus placebo (PBO), each with optimized background therapy (N = 1047). A repeated measures model evaluated longitudinal CD4 changes, multivariate linear regression evaluated predictors of week 48 increases, and Cox proportional hazard modeling evaluated time to category C events. Results: Median CD4 increases were greater on MVC once or twice daily than PBO (92, 103, and 24 cells/mm3, respectively; P < 0.05), and the difference remained significant among patients achieving less than 50 HIV-1 RNA copies/mL (126, 125, and 96 cells/mm3; P < 0.05) or when adjusted for other predictors of CD4 increase including change in HIV-1 RNA. Time to a category C event was longer on MVC; in multivariate models, higher on-treatment CD4 count, but not MVC treatment, was protective against new events (hazard ratio 0.8 per +25 cells/mm3; 95% confidence interval 0.78-0.87). Conclusions: MOTIVATE patients receiving MVC had larger CD4+ T-cell increases than those receiving PBO, even after adjusting for the greater virologic potency of MVC-containing regimens. This additional CD4 response was associated with a longer time to the development of AIDS-defining events on MVC.

AB - Objectives: To determine factors associated with CD4 responses to maraviroc (MVC)-containing regimens in treatment-experienced patients. Methods: Forty-eight-week data from MOTIVATE 1 and 2 was used to assess MVC once or twice daily versus placebo (PBO), each with optimized background therapy (N = 1047). A repeated measures model evaluated longitudinal CD4 changes, multivariate linear regression evaluated predictors of week 48 increases, and Cox proportional hazard modeling evaluated time to category C events. Results: Median CD4 increases were greater on MVC once or twice daily than PBO (92, 103, and 24 cells/mm3, respectively; P < 0.05), and the difference remained significant among patients achieving less than 50 HIV-1 RNA copies/mL (126, 125, and 96 cells/mm3; P < 0.05) or when adjusted for other predictors of CD4 increase including change in HIV-1 RNA. Time to a category C event was longer on MVC; in multivariate models, higher on-treatment CD4 count, but not MVC treatment, was protective against new events (hazard ratio 0.8 per +25 cells/mm3; 95% confidence interval 0.78-0.87). Conclusions: MOTIVATE patients receiving MVC had larger CD4+ T-cell increases than those receiving PBO, even after adjusting for the greater virologic potency of MVC-containing regimens. This additional CD4 response was associated with a longer time to the development of AIDS-defining events on MVC.

KW - CCR5 antagonist

KW - CD4 cell rises

KW - clinical trials

KW - immune restoration

KW - maraviroc

KW - opportunistic infections

KW - treatment-experienced patients

UR - http://www.scopus.com/inward/record.url?scp=77955501291&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955501291&partnerID=8YFLogxK

U2 - 10.1097/QAI.0b013e3181c5c83b

DO - 10.1097/QAI.0b013e3181c5c83b

M3 - Article

C2 - 20009949

AN - SCOPUS:77955501291

VL - 54

SP - 394

EP - 397

JO - Journal of acquired immune deficiency syndromes (1999)

JF - Journal of acquired immune deficiency syndromes (1999)

SN - 1525-4135

IS - 4

ER -